.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,361,794

« Back to Dashboard

Details for Patent: 6,361,794

Title: Method of making ibuprofen and narcotic analgesic composition
Abstract:Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process; (b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material; and (c) compressing the blend into a tablet.
Inventor(s): Kushla; Gregory P. (Florham Park, NJ), Lai; Jin-Wang (Edison, NJ), Polli; Gerald P. (Valley Forge, PA)
Assignee: BASF Corporation (Mt. Olive, NJ)
Filing Date:Jun 10, 1997
Application Number:08/872,217
Claims:1. A method of making a pharmaceutical tablet composition comprising: (a) granulating ibuprofen, hydrocodone bitartrate, colloidal silicon dioxide, a disintegrant, a filler and starch to form granules wherein said granulating step comprises a wet granulation process; (b) blending the granules with extra-granular material comprised of a lubricant and at least one excipient to form a blend of granules and extra granular material wherein the composition is substantially free of lactose and polyvinylpyrrolidone and wherein the blend flows well, has good compression performance, and can be compressed over a wide range of compression forces with no substantial change in the disintegration time of a tablet made from such blend; (c) compressing the blend into a tablet, wherein said ibuprofen, said hydrocodone bitartrate and said lubricant are present in said tablet in a single phase.

2. The method as recited in claim 1 wherein the ibuprofen is provided in a range of about 25% to about 63%, by total weight of the tablet; the hydrocodone bitartrate is provided in a range of about 0.6% to about 3.8%, by total weight of the tablet; the colloidal silicon dioxide is provided in a range of about 0.5% to about 3% by total weight of the tablet; the filler is selected from the group consisting of microcrystalline cellulose and powdered cellulose and is provided in range of the total weight of the tablet of about 10% to about 42%; the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate and is provided in a range, of the total weight of the tablet, of about 4% to about 10%; the binder comprises an alkylhydroxy methylcellulose and binder is provided in a range, of the total weight of the tablet composition, of about 2% to less than 6%; the starch is provided in a range, of the total weight of the tablet composition, of about 11% to about 20%; and the lubricant is provided in an amount less than 1% by weight of the total weight of the tablet;

and wherein the granule comprises granulate material comprised of: 1) the ibuprofen, 2) the hydrocodone, 3) about 0.5% to about 2.0%, of the total weight of the tablet composition, of colloidal silicon dioxide, 4) about 9.5% up to about 22%, of the total weight of the tablet composition, of filler, 5) about 4%, of the total weight of the tablet composition, of disintegrant, and 6) about 6% to about 12%, of the total weight of the tablet composition of starch;

wherein the extra granule material comprises the remaining amount of the tablet material; the composition provided in the substantial absence of lactose and/or polyvinylpyrrolidone and wherein the composition flows well, has good compression performance, and can be compressed over a wide range of compression forces with no substantial change in the disintegration time of the tablet.

3. The method as recited in claim 2 wherein the weight of the filler is provided in range, of the total weight of the tablet composition, of about 15% to about 25%.

4. The method as recited in claim 2 wherein the weight of the disintegrant is provided in a range of about 6% to about 8%.

5. The method as recited in claim 3 wherein the weight of the disintegrant is provided in a range of about 6% to about 8%.

6. The method as recited in claim 2 wherein the weight of the colloidal silicon dioxide is in a range of the total weight of the tablet, of about 1.5% to about 2%.

7. The method as recited in claim 3 wherein the weight of the colloidal silicon dioxide is in a range, of the total weight of the tablet, of about 1.5% to about 2%.

8. The method as recited in claim 4 wherein the weight of the colloidal silicon dioxide is in a range, of the total weight of the tablet, of about 1.5% to about 2%.

9. The method as recited in claim 5 wherein the weight of the colloidal silicon dioxide is in a range, of the total weight of the tablet, of about 1.5% to about 2%.

10. The method as recited in claim 2 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

11. The method as recited in claim 3 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

12. The method as recited in claim 4 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

13. The method as recited in claim 5 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

14. The method as recited in claim 6 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

15. The method as recited in claim 7 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

16. The method as recited in claim 8 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

17. The method as recited in claim 9 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

18. The method as recited in claim 2 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

19. The method as recited in claim 3 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

20. The method as recited in claim 4 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

21. The method as recited in claim 5 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

22. The method as recited in claim 6 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

23. The method as recited in claim 7 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

24. The method as recited in claim 8 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

25. The method as recited in claim 9 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

26. The method as recited in claim 10 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

27. The method as recited in claim 11 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

28. The method as recited in claim 12 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

29. The method as recited in claim 13 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

30. The method as recited in claim 14 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

31. The method as recited in claim 15 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

32. The method as recited in claim 16 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

33. The method as recited in claim 17 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc